Atlas Trials

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

Clinical trial NCT05298722 · RECRUITING

Trial details

NCT number
NCT05298722
Sponsor
University Hospital, Ghent
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2022-12-12
Primary completion
2026-03-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.